Tandem Diabetes Care Inc (TNDM) CFO Sells $704,500.00 in Stock

Tandem Diabetes Care Inc (NASDAQ:TNDM) CFO Leigh Vosseller sold 10,000 shares of Tandem Diabetes Care stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $70.45, for a total value of $704,500.00. Following the completion of the sale, the chief financial officer now owns 12,009 shares of the company’s stock, valued at $846,034.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Leigh Vosseller also recently made the following trade(s):

  • On Friday, May 3rd, Leigh Vosseller sold 10,000 shares of Tandem Diabetes Care stock. The shares were sold at an average price of $65.14, for a total value of $651,400.00.

Shares of Tandem Diabetes Care stock opened at $67.13 on Friday. Tandem Diabetes Care Inc has a one year low of $11.57 and a one year high of $74.81. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of -26.33 and a beta of 0.63.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Tuesday, April 30th. The medical device company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.10). Tandem Diabetes Care had a negative return on equity of 40.76% and a negative net margin of 50.73%. The business had revenue of $66.00 million for the quarter, compared to analysts’ expectations of $47.55 million. During the same quarter in the previous year, the firm posted ($1.82) EPS. Tandem Diabetes Care’s revenue was up 141.9% on a year-over-year basis. On average, equities analysts predict that Tandem Diabetes Care Inc will post -0.88 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the company. Sigma Planning Corp purchased a new stake in shares of Tandem Diabetes Care during the fourth quarter worth about $290,000. Bank of America Corp DE grew its stake in shares of Tandem Diabetes Care by 250.1% during the fourth quarter. Bank of America Corp DE now owns 121,451 shares of the medical device company’s stock worth $4,613,000 after acquiring an additional 86,763 shares during the last quarter. Teachers Advisors LLC grew its stake in shares of Tandem Diabetes Care by 11.9% during the third quarter. Teachers Advisors LLC now owns 99,521 shares of the medical device company’s stock worth $4,263,000 after acquiring an additional 10,576 shares during the last quarter. Emerald Advisers LLC grew its stake in shares of Tandem Diabetes Care by 22.8% during the fourth quarter. Emerald Advisers LLC now owns 772,093 shares of the medical device company’s stock worth $29,316,000 after acquiring an additional 143,587 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in shares of Tandem Diabetes Care by 2.3% during the fourth quarter. California State Teachers Retirement System now owns 79,809 shares of the medical device company’s stock worth $3,030,000 after acquiring an additional 1,800 shares during the last quarter. Institutional investors and hedge funds own 81.03% of the company’s stock.

Several research firms recently weighed in on TNDM. Bank of America restated a “neutral” rating and issued a $65.00 price objective on shares of Tandem Diabetes Care in a report on Friday. ValuEngine upgraded shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Svb Leerink assumed coverage on shares of Tandem Diabetes Care in a report on Monday, May 13th. They issued an “outperform” rating and a $83.00 target price for the company. Leerink Swann assumed coverage on shares of Tandem Diabetes Care in a report on Monday, May 13th. They issued an “outperform” rating and a $83.00 target price for the company. Finally, Oppenheimer boosted their target price on shares of Tandem Diabetes Care from $68.00 to $80.00 and gave the stock an “outperform” rating in a report on Wednesday, May 1st. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Tandem Diabetes Care has a consensus rating of “Buy” and a consensus target price of $68.13.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/19/tandem-diabetes-care-inc-tndm-cfo-sells-704500-00-in-stock.html.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Story: Understanding Specialty Certificates of Deposit

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.